Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: A meta-analysis

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Pang, Bo ^a   Cheng, Shi ^a   Sun, Shi Peng ^a   An, Cheng ^a   Liu, Zhi Yuan ^a   Feng, Xue ^a   Liu, Gui Jian ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROGESTERONE RECEPTOR;

BREAST TUMOR; EXON; FEMALE; GENETICS; HUMAN; META ANALYSIS; MUTATION; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE;

BREAST NEOPLASMS; EXONS; FEMALE; HUMANS; MUTATION; NEOPLASM RECURRENCE, LOCAL; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84906883412     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06255     Document Type: Article

References (49)

1. Network, C. G. A. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
2. Boswell, K. A., Wang, X., Shah, M. V. & Aapro, M. S. Disease burden and treatment outcomes in second-line therapy of patients with estrogen receptorpositive (ER1) advanced breast cancer: a review of the literature. Breast 21, 701-706 (2012).
3. Glass, A. G., Lacey, J. V., Jr., Carreon, J. D. & Hoover, R. N. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99, 1152-1161 (2007). (Pubitemid 47233065)
4. OBrien, C. et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 39 kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 16, 3670-3683 (2010).
5. Mangone, F. R., Bobrovnitchaia, I. G., Salaorni, S., Manuli, E. & Nagai, M. A. PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients. Clinics (Sao Paulo) 67, 1285-1290 (2012).
6. Drury, S. C. et al. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr Relat Cancer 18, 565-577 (2011).
7. Boulay, A. et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 11, 5319-5328 (2005). (Pubitemid 41003721)
8. Crowder, R. J. et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 69, 3955-3962 (2009).
9. Bachman, K. E. et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3, 772-775 (2004). (Pubitemid 41351083)
10. Barbareschi, M. et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 13, 6064-6069 (2007). (Pubitemid 350075063)
11. Beelen, K. et al. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2 and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Breast Cancer Res 16, R13 (2014).
12. Benvenuti, S. et al. PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat 29, 284-288 (2008). (Pubitemid 351240601)
13. Bozhanov, S. S. et al. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer. J Cancer Res Clin Oncol 136, 1657-1669 (2010).
14. Buttitta, F. et al. PIK3CAmutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol 208, 350-355 (2006). (Pubitemid 43210521)
15. Campbell, I. G. et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64, 7678-7681 (2004). (Pubitemid 39446895)
16. Cizkova, M. et al. PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups. Breast Cancer Res 14, R28 (2012).
17. Cuorvo, L. V. et al. PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy. Virchows Archiv: an international journal of pathology 464, 85-93 (2014).
18. Dunlap, J. et al. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat 120, 409-418 (2010).
19. Dupont Jensen, J. et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 17, 667-677 (2011).
20. Ellis, M. J. et al. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat 119, 379-390 (2010).
21. Gonzalez-Angulo, A. M. et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 15, 2472-2478 (2009).
22. Harle, A. et al. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria. Oncology reports 29, 1043-1052 (2013).
23. Jensen, J. D. et al. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 23, 2034-2042 (2012).
24. Kalinsky, K. et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15, 5049-5059 (2009).
25. Lai, Y. L. et al. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol 15, 1064-1069 (2008).
26. Li,H. et al. PIK3CAmutations mostly begin to develop in ductal carcinoma of the breast. Exp Mol Pathol 88, 150-155 (2010).
27. Li, S. Y., Rong, M., Grieu, F. & Iacopetta, B. PIK3CAmutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 96, 91-95 (2006).
28. Liang, X. et al. Mutational hotspot in exon 20 of PIK3CA in breast cancer among Singapore Chinese. Cancer Biol Ther 5, 544-548 (2006). (Pubitemid 43765291)
29. Liedtke, C. et al. PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res 10, R27 (2008).
30. Lin, C. H. et al. Prognosticmolecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients? J Clin Pathol 64, 781-787 (2011).
31. Loi, S. et al. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. JNatl Cancer Inst 105, 960-967 (2013).
32. Lopez-Knowles, E. et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 126, 1121-1131 (2010)
33. Maruyama, N. et al. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 13, 408-414 (2007). (Pubitemid 46225343)
34. Michelucci, A. et al. PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases. Diagn Mol Pathol 18, 200-205 (2009).
35. Perez-Tenorio, G. et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 13, 3577-3584 (2007). (Pubitemid 46955118)
36. Saal, L. H. et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65, 2554-2559 (2005). (Pubitemid 40490050)
37. Sanchez, C. G. et al. Preclinical modeling of combined phosphatidylinositol-3- kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 13, R21 (2011).
38. Santarpia, M. et al. PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance. Cancer Invest 26, 1044-1051 (2008).
39. Stemke-Hale, K. et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68, 6084-6091 (2008).
40. Ioannidis, J. P. & Trikalinos, T. A. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ 176, 1091-1096 (2007). (Pubitemid 46649731)
41. Cizkova, M. et al. Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway. PLoS One 5, e15647 (2010).
42. Ford, C. E., Ekstrom, E. J., Howlin, J. & Andersson, T. The WNT-5a derived peptide, Foxy-5, possesses dual properties that impair progression of ERalpha negative breast cancer. Cell Cycle 8, 1838-1842 (2009).
43. Campisi, J. & dAdda di Fagagna, F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8, 729-740 (2007). (Pubitemid 47312822)
44. Dumont, A. G., Dumont, S. N. & Trent, J. C. The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer. Chin J Cancer 31, 327-334 (2012).
45. Loi, S. et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A 107, 10208-10213 (2010).
46. Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25, 603-605 (2010).
47. Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S. & Sydes, M. R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8, 16 (2007).
48. Lau, J., Ioannidis, J. P. & Schmid, C. H. Quantitative synthesis in systematic reviews. Ann Intern Med 127, 820-826 (1997). (Pubitemid 27465551)
49. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin Trials 7, 177-188 (1986). (Pubitemid 17189972)